Ultragenyx PharmaceuticalRARE
RARE
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
29% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 42
4% more funds holding
Funds holding: 298 [Q3] → 309 (+11) [Q4]
1.69% more ownership
Funds ownership: 93.24% [Q3] → 94.93% (+1.69%) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 108
17% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]
17% less call options, than puts
Call options by funds: $31.5M | Put options by funds: $37.9M
23% less capital invested
Capital invested by funds: $4.77B [Q3] → $3.68B (-$1.09B) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$95
168%
upside
Avg. target
$116
228%
upside
High target
$136
284%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama 16% 1-year accuracy 10 / 61 met price target | 231%upside $117 | Overweight Maintained | 27 Mar 2025 |
Piper Sandler Allison Bratzel 36% 1-year accuracy 4 / 11 met price target | 225%upside $115 | Overweight Maintained | 17 Mar 2025 |
Cantor Fitzgerald Kristen Kluska 24% 1-year accuracy 24 / 101 met price target | 233%upside $118 | Overweight Reiterated | 26 Feb 2025 |
HC Wainwright & Co. Ed Arce 32% 1-year accuracy 49 / 152 met price target | 168%upside $95 | Buy Reiterated | 18 Feb 2025 |
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 11 / 44 met price target | 284%upside $136 | Buy Maintained | 18 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
5 days ago
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key catalysts include the FDA's Priority Review of UX111 for Sanfilippo syndrome type A, with a PDUFA date set for August 2025.
Positive
Zacks Investment Research
1 week ago
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
1 month ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company's common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
Neutral
GlobeNewsWire
2 months ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the company's common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Zacks Investment Research
2 months ago
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Neutral
Seeking Alpha
2 months ago
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Gena Wang - Barclays Yaron Werber - TD Cowen Joon Lee - Truist Securities Jeff Hung - Morgan Stanley Rick Miller - Cantor Fitzgerald Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode.
Positive
Zacks Investment Research
2 months ago
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
2 months ago
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Charts implemented using Lightweight Charts™